2023
CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
Han R, Li J, Hony J, Xiao Z, wang J, Yao M, Liang S, Lu L. CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment. Frontiers In Immunology 2023, 14: 1052657. PMID: 37006233, PMCID: PMC10061011, DOI: 10.3389/fimmu.2023.1052657.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsC motif chemokine ligand 8Hepatocellular carcinomaCheckpoint inhibitorsDeath ligand 1 (PD-L1) immunotherapyCell death protein 1Treatment of HCCDeath protein 1Chemokine ligand 8Function of monocytesTumor immunosuppression microenvironmentClinical benefitCombination therapyImmunosuppression microenvironmentLethal malignancyTherapeutic effectEffective treatmentHCC treatmentAdvanced stageProtein 1Ligand 8ImmunotherapyTreatmentXII inhibitorsAnticancer drugs
2019
Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes
Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.Peer-Reviewed Original ResearchConceptsType 2 cancerHormone replacement therapyCox regression modelType 2 diseaseRisk factorsEndometrial cancerType 1Use of HRTLess obese patientsBaseline risk factorsEndometrial cancer casesMajor cardiovascular diseasesObese patientsOral contraceptivesOverall survivalClinical courseDiabetes mellitusRetrospective reviewRegression modelsReplacement therapyCardiovascular diseaseCancer casesAdvanced stageHigh mortalityRecurrence